Merck Launches Shorespan-007 Clinical Trial of Bomedemstat for Essential Thrombocythemia
Shorespan-007 is expected to enroll approximately 300 patients with essential thrombocythemia and will compare bomedemstat to hydroxyurea, the current standard of care.
